Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

Nirmatrelvir-ritonavir effectively lowers hospitalization rates and long COVID symptoms in non-hospitalized, high-risk patients with mild to moderate COVID-19.

By Jack Phillips Contributing Writer Recent estimates published by the U.S. Centers for Disease Control and Prevention show ...

Crews searched for bodies Thursday as people tried to salvage what they could following monstrous flash floods in Spain.

A 14-day course of the oral anti-inflammatory drug montelukast didn't shorten symptom duration in nonhospitalized US adults with mild or moderate COVID-19, finds a randomized controlled clinical trial ...

Check out royalpurplenews.com and visit local distribution stands for newspapers. News sections include news, opinions, arts ...

At the moment, there is no information on how quickly the new vaccine ... and NHS to make Spikevax Bivalent Original/Omicron available to the UK public," said Moderna in a statement.

On NBC 10 News Today, Alpha Omicron PI at the University of Louisiana Monroe just finished their Annual funding for the ...

Researchers at Kumamoto University have made a significant breakthrough in the fight against COVID-19 with the development of ...

Serving as a classroom teacher before officially graduating may sound intimidating, but Goodman seized the opportunity to ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...